Fulgent Corp - FLGT Net earnings per share for the last four quarters

Official company branding of Fulgent Corp (FLGT)

Fulgent Genetics, Inc. (FLGT) management is pivoting its strategy from pandemic testing toward oncogenetics, a shift reflected in the securities' price action. The current annual EPS TTM growth value demonstrates a struggle among traders within a sideways trend, where the status is -120.40. Contracts with insurance networks provide stable revenue, while the technological superiority of US laboratories is maintained through the implementation of new diagnostic methods.

FLGT Fulgent: Net earnings per share (EPS TTM) in the range 02/11/2024 - 11/17/2026

FLGT (Fulgent Genetics, Inc.): analytical breakdowns and indicator data

- market price and analyst price targets:
Fundamental company valuation:FLGT Fulgent Genetics
Mass-produced product of Fulgent

This metric measures the annual growth rate of net income per share, utilizing a 12-month rolling window to neutralize quarterly volatility. By analyzing the EPS YoY growth rate (trailing 12 months), an investor can discern the actual impact of declining diagnostic margins and insurance limit pressures on the bottom-line profitability of Fulgent Genetics, Inc. (FLGT), enabling an assessment of the business's post-pandemic resilience.

Competitor analysis for Fulgent Genetics, Inc.

A - Net earnings per share (EPS TTM)|Quest Corp (DGX) - Earnings per share for the last twelve months|ILMN - Net earnings per share for the last four quarters|Earnings per share for the last twelve months exactsciences.com|revvity.com (RVTY) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) BIO|Net earnings per share (EPS TTM) Anbio Biotechnology Ltd (NNNN)|Sotera Health - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) QuidelOrtho Corp QDEL|OPK - Earnings per share for the last twelve months|Earnings per share for the trailing year CDNA (caredx.com)|MRVI: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months LAB|Earnings per share for the last twelve months Cytek Biosciences Inc|Net earnings per share (EPS TTM) OraSure Corp|Net earnings per share for the last 12 months XGN (Exagen Inc)|Net earnings per share (EPS TTM) mdxhealth.com (MDXH)|Net earnings per share (EPS TTM) LUCD (Lucid Diagnostics Inc)|PRE - Net earnings per share for the last 12 months|IMDX: Net earnings per share for the last 12 months|Earnings per share for the trailing year TRIB (trinitybiotech.com)|PRPH (ProPhase Labs, Inc.) - Net earnings per share for the last 12 months|Net earnings per share for the last 12 months Ainos|Earnings per share for the last twelve months Co-Diagnostics Inc|HSCS (Heart Test Laboratories Inc.) - Earnings per share for the last four quarters|Net earnings per share (EPS TTM) BMRA|Cardio Diagnostics Holdings Inc. (CDIO) - Net earnings per share for the trailing year|Earnings per share for the last twelve months Onconetix ONCO|viraxbiolabs.com - Earnings per share for the last twelve months|BJDX - Earnings per share for the last twelve months|Earnings per share for the trailing year AWH (Aspira Women's Health Inc.)|AXDX: Net earnings per share (EPS TTM)|CNTG - Net earnings per share for the last four quarters|ENZ (enzo.com) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months FRES|Earnings per share for the last twelve months Genetic Technologies (GENE)|Net earnings per share for the last four quarters 23andMe Holding Co|Net earnings per share (EPS TTM) PMD (Psychemedics)